信使核糖核酸
dna疫苗
临床试验
接种疫苗
医学
癌症
计算生物学
抗原
病毒学
生物信息学
癌症研究
生物
免疫学
基因
免疫
遗传学
内科学
作者
Tian Tan,Shuting Deng,Bing-Huo Wu,Qi Yang,Mengwan Wu,Hong Wu,Chenhui Cao,Chuan Xu
标识
DOI:10.2174/1568009623666230222124424
摘要
Abstract:: The corresponding mRNA vaccines Comirnaty (BNT162b2) and Spikevax (mRNA-1273) have been authorized for emergency use since the COVID-19 outbreak. Most clinical researches have also discovered that the mRNA vaccine is a revolutionary strategy for preventing and treating numer-ous diseases, including cancers. Unlike viral vectors or DNA vaccines, mRNA vaccines cause the body to directly produce proteins following injection. Delivery vectors and mRNAs that encode tumor antigens or immunomodulatory molecules work together to trigger an anti-tumor response. Before mRNA vaccines may be employed in clinical trials, a number of challenges need to be resolved. These include establishing effective and safe delivery systems, generating successful mRNA vaccines against diverse types of cancers, and proposing improved combination therapy. Therefore, we need to improve vaccine-specific recognition and develop mRNA delivery mechanisms. This review summa-rizes the complete mRNA vaccines’ elemental composition and discusses recent research progress and future direction for mRNA tumor vaccines.
科研通智能强力驱动
Strongly Powered by AbleSci AI